InsidersTradesSigma
Total declarations
Companies
▲ Purchases (19 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
19
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Rosenwald Lindsay A Md, Director. Officer active across 5 companies, notably Checkpoint Therapeutics, Inc.. In total, 41 reports have been recorded. Breakdown: 19 buys · 0 sell. Total volume traded: €6.7m. History available since 10 June 2021. The latest transaction was filed on 18 March 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Rosenwald Lindsay A Md
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations41 total
10,000 sharesCommon Stock, $0.0001 par valueSEC:0001104659-26-078266:0
475,424 shares0Common stock, par value $0.001SEC:0000941841-26-000002:0
50,000 shares0Common Stock, $0.0001 par valueSEC:0001104659-25-075272:0
7,173 shares0Common Stock, $0.0001 par valueSEC:0001104659-25-066239:0
12,195 shares0COMMON STOCKSEC:0001104659-25-054692:0
50,000 shares@ US$1.29100.0% of flowCOMMON STOCKSEC:0001104659-25-054692:1
207,007 sharesCOMMON STOCKSEC:0001104659-25-054692:2
454,153 shares0Common stock, par value $0.001SEC:0001415889-25-000400:0
12,638 shares0COMMON STOCKSEC:0001104659-24-129526:0
763,359 shares@ US$1.8420.5% of flowCommon stock, par value $0.001SEC:0001415889-24-023957:0
Canonical exit: 22 Dec 2024 (T+90)
5,000 shares@ US$7.48350.6% of flowSERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-24-079855:0
Canonical exit: 9 Oct 2024 (T+90)
5,000 shares@ US$7.39420.6% of flowSERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-24-079100:0
Canonical exit: 7 Oct 2024 (T+90)
5,000 shares@ US$7.35290.6% of flowSERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-24-078786:0
Canonical exit: 6 Oct 2024 (T+90)
9,728 shares0Common Stock, $0.0001 par valueSEC:0001104659-24-078968:0
20,000 shares@ US$1.63620.5% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-24-076591:0
Canonical exit: 26 Sept 2024 (T+90)
10,000 shares@ US$1.75890.3% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-24-063455:0
Canonical exit: 14 Aug 2024 (T+90)
32,051 shares0COMMON STOCKSEC:0001104659-24-062664:0
10,000 shares@ US$3.049.4% of flowCommon Stock, $0.0001 par valueSEC:0001104659-24-039354:0
Canonical exit: 23 Jun 2024 (T+90)
20,000 shares@ US$3.4021.0% of flowCommon Stock, $0.0001 par valueSEC:0001104659-24-038431:0
Canonical exit: 20 Jun 2024 (T+90)
50,000 shares@ US$2.37541.8% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-24-002464:0
Canonical exit: 4 Apr 2024 (T+90)
216,465 shares0COMMON STOCK, PAR VALUE $0.001SEC:0001104659-24-000898:0
1,567,515 shares@ US$1.7040.5% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-23-119188:0
Canonical exit: 12 Feb 2024 (T+90)
100,000 shares@ US$0.28331.3% of flowCOMMON STOCK, PAR VALUE $0.001SEC:0001104659-23-104099:0
Canonical exit: 25 Dec 2023 (T+90)
348,675 shares@ US$0.72100.0% of flowCommon StockSEC:0001437749-23-025643:0
Canonical exit: 7 Dec 2023 (T+90)
100,000 shares@ US$2.2369.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001104659-23-099229:0
Canonical exit: 5 Dec 2023 (T+90)
25 of 41 declarations
About Rosenwald Lindsay A Md
ROSENWALD LINDSAY A MD is Président, Directeur Général et Administrateur. He has 41 filings in total, and across the sampled recent filings, all transactions are buys for EUR 6683541, with no sales, between 2016-01-05 and 2026-06-26. The recent filings concern Fortress Biotech, Inc., Journey Medical Corp and Avenue Therapeutics, INC., with the transaction nature shown as Attribution.
